Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Other Operating Expenses: 2016-2025

Historic Other Operating Expenses for Akebia Therapeutics (AKBA) over the last 7 years, with Sep 2025 value amounting to $578,000.

  • Akebia Therapeutics' Other Operating Expenses rose 42.36% to $578,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 38.74%. This contributed to the annual value of $1.8 million for FY2024, which is 435.50% up from last year.
  • Akebia Therapeutics' Other Operating Expenses amounted to $578,000 in Q3 2025, which was down 0.34% from $580,000 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Other Operating Expenses registered a high of $1.0 million during Q4 2021, and its lowest value of $170,000 during Q1 2023.
  • In the last 3 years, Akebia Therapeutics' Other Operating Expenses had a median value of $462,000 in 2023 and averaged $450,455.
  • In the last 5 years, Akebia Therapeutics' Other Operating Expenses surged by 314.29% in 2021 and then slumped by 62.14% in 2023.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Other Operating Expenses stood at $1.0 million in 2021, then crashed by 56.85% to $444,000 in 2022, then grew by 4.05% to $462,000 in 2023, then surged by 39.18% to $643,000 in 2024, then skyrocketed by 42.36% to $578,000 in 2025.
  • Its last three reported values are $578,000 in Q3 2025, $580,000 for Q2 2025, and $387,000 during Q1 2025.